Total amount: € 0,00
A Journal on Nuclear Medicine and Molecular Imaging
Affiliated to the and to the International Research Group of Immunoscintigraphy
Indexed/Abstracted in: Current Contents/Clinical Medicine, EMBASE, PubMed/MEDLINE, Science Citation Index (SciSearch), Scopus
Impact Factor 2,413
Online ISSN 1827-1936
Zerva B., Koutsikos J., Palestidis C., Kounadi E., Gerali S.
Department of Nuclear Medicine Alexandra University Hospital, Athens, Greece
Aim. To test the hypothesis that the ratio of thyroglobulin (Tg) to 131I uptake in the thyroid bed during the immediate post-thyroidectomy work-up could be used before first 131I treatment to detect patients with residual or metastatic thyroid cancer and justify the administration of a higher ablation dose in selected cases and a possibly better therapeutic effect.
Methods. We retrospectively studied 293 patients with differentiated thyroid carcinoma that received their first 131I treatment in our department. Patients with Tg >100 ng/mL, 131I uptake >10% and measurable Tg-specific autoantibodies, were excluded. According to the post-therapy total body scan (TBS), we divided them in 2 groups: group I, without metastases (negative TBS), and group II, with metastases (positive TBS). The ratio of Tg to 131I uptake measured before the first 131I treatment was calculated in both groups.
Results. A total of 248 patients were included in the study; 225 in group I and 23 in group II. Tg to 131I uptake ratio was significantly lower in group I (mean 2.17 ng/mL/%, range 0-36), than in group II (mean 32.7 ng/mL/%, range 2.14-220), (P<0.01). The sensitivity, specificity and accuracy (using a threshold ratio 7 ng/mL/% as normal) were all 95.6% for predicting a positive post-therapy TBS.
Conclusion. The use of a threshold ratio 7 ng/mL/% as the upper limit of normal provides useful information with higher sensitivity and specificity in identifying patients with metastatic disease creating the possibility for the selective use of higher initial iodine therapy doses.